Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010
January 21 2010 - 8:30AM
PR Newswire (US)
Updated Results from Phase 2 Clinical Trial of KRX-0401 in
Combination with Capecitabine for the treatment of Metastatic Colon
Cancer to be Presented on Sunday, January 24, 2010 NEW YORK, Jan 21
/PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
(NASDAQ:KERX) today announced that updated results from its Phase 2
clinical trial of KRX-0401 (perifosine) in combination with
capecitabine has been selected for poster presentation at the
upcoming ASCO 2010 Gastrointestinal Cancers Symposium, to be held
in Orlando, Florida from January 22-24, 2010. The clinical data to
be presented demonstrates the potential safety and efficacy of
KRX-0401 in the treatment of patients with metastatic colon cancer.
Details on the poster presentation are as follows: Abstract #: 447
TITLE: A Randomized phase II study of perifosine in combination
with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in
patients with second- or third-line metastatic colon cancer (mCRC):
Updated results Lead Author: Johanna Bendell, MD Session Name:
General Poster Session C: Cancers of the Colon and Rectum Date:
Sunday, January 24, 2010 Presentation Time: 7:00 AM - 8:00 AM;
12:00 NOON - 1:00 PM A copy of the above referenced abstract can be
viewed online through the American Society of Clinical Oncology's
website, http://www.asco.org/. KRX-0401 (perifosine) is in-licensed
by Keryx from Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) in the
United States, Canada and Mexico. About Keryx Biopharmaceuticals,
Inc. Keryx Biopharmaceuticals is focused on the acquisition,
development and commercialization of medically important
pharmaceutical products for the treatment of life-threatening
diseases, including cancer and renal disease. Keryx is developing
KRX-0401 (perifosine), a novel, potentially first-in-class, oral
anti-cancer agent that inhibits the phosphoinositide 3-kinase
(PI3K)/Akt pathway, a key signaling cascade that has been shown to
induce cell growth and cell transformation. KRX-0401 has
demonstrated both safety and clinical efficacy in several tumor
types, both as a single agent and in combination with novel
therapies. KRX-0401 also modulates a number of other key signal
transduction pathways, including the JNK pathway, which are
pathways associated with programmed cell death, cell growth, cell
differentiation and cell survival. KRX-0401 is currently in a Phase
3 trial, under Special Protocol Assessment (SPA), in multiple
myeloma, and in Phase 2 clinical development for several other
tumor types. Keryx is also developing Zerenex(TM) (ferric citrate),
an oral, iron-based compound that has the capacity to bind to
phosphate and form non-absorbable complexes. The Phase 3 clinical
program of Zerenex in the treatment for hyperphosphatemia (elevated
phosphate levels) in patients with end-stage renal disease is
expected to begin this quarter under an SPA agreement with the FDA.
Keryx is headquartered in New York City. Cautionary Statement Some
of the statements included in this press release, particularly
those anticipating future clinical and business prospects for
KRX-0401 (perifosine), may be forward-looking statements that
involve a number of risks and uncertainties. For those statements,
we claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995. Among the factors that could cause our actual results
to differ materially are the following: our ability to successfully
complete clinical trials for KRX-0401; our ability to meet
anticipated development timelines for KRX-0401 due to recruitment,
clinical trial results, manufacturing capabilities or other
factors; and other risk factors identified from time to time in our
reports filed with the Securities and Exchange Commission. Any
forward-looking statements set forth in this press release speak
only as of the date of this press release. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release
and prior releases are available at http://www.keryx.com/. The
information in our website and in the American Society of Clinical
Oncology's website is not incorporated by reference into this press
release and is included as an inactive textual reference only.
KERYX CONTACT: Lauren Fischer Director, Investor Relations Keryx
Biopharmaceuticals, Inc. Tel: 212.531.5962 E-mail: DATASOURCE:
Keryx Biopharmaceuticals, Inc. CONTACT: Lauren Fischer, Director,
Investor Relations, Keryx Biopharmaceuticals, Inc.,
+1-212-531-5962, Web Site: http://www.keryx.com/
Copyright